Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy?
Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy?
复制标题
DOI：
10.1016/0959-8049(95)00421-1
复制
发表时间：
1995-11-01
影响因子：
8.4
通讯作者：
Jones, T
中科院分区：
文献类型：
--
作者：
Price, P;Jones, T
在1994年于阿姆斯特丹举行的EORTC NCI新药开发会议上，根据EC PET（正电子发射断层扫描）肿瘤学协调行动的建议，举办了一次研讨会，汇集了许多欧洲PET中心，这些中心正在研究使用[F-18]FDG（[F-18]2-氟-2-脱氧葡萄糖）PET扫描作为癌症治疗反应的衡量标准。在欧洲目前31个应邀提供资料的PET中心中，15个中心已经有数据，其他中心也表示有兴趣。许多研究小组与当地肿瘤学家合作，用这种技术测量肿瘤对化疗（12组）和放疗（3组）的反应。尽管方法学存在差异，且数据解释存在困难，但肿瘤[F-18]FDG摄取评估被认为是肿瘤功能成像、评估代谢率和提供肿瘤缓解措施的合理方法。概括地说，汇总经验，似乎在一个或两个周期的化疗治疗后[F-18]FDG肿瘤摄取的变化与最终的临床反应有关。显示[F-18]FDG摄取减少最多的患者获得了最佳的临床反应。还提供了关于化疗对正常组织的影响的数据，以及关于放射治疗的影响和肿瘤反应的一些数据。得出的结论是，在[F-18]FDG摄取的变化与PET测量可能提供有用的信息，临床以及亚临床肿瘤抗癌治疗的反应。这可能是有用的，作为一个指导，以早期反应的治疗，以及提供功能评估的残余肿块的疾病。更特异的细胞增殖标记物，例如[（11）]胸苷或[C-11]-氨基酸，可以提供更准确的信息。概述了一种策略，即PET扫描方案可以平行EORTC早期临床试验，以便[F-18]FDG反应信息可以补充I期和II期临床研究。在这些发展之后，在EORTC研究分支的主持下成立了EORTC研究小组，并概述了欧洲未来发展的战略。
At the EORTC NCI New Drug Development Meeting in Amsterdam in 1994, a workshop, suggested by the EC PET (positron emission tomography) Oncology concerted action, was held to bring together many of those European PET centres investigating the use of [F-18]FDG ([F-18]2-fluoro-2 deoxyglucose) PET scanning as a measure of response to cancer therapy. Of the current 31 PET centres in Europe invited to contribute, 15 centres already had data and others expressed interest. Many of the groups were collaborating with local oncologists to measure tumour response to chemotherapy (12 groups) and radiotherapy (three groups) with this technique. Despite variations of methodology, and difficulties in data interpretation, assessment of tumour [F-18]FDG uptake was thought to be a reasonable method for the functional imaging of tumours, assessing metabolic rate and providing a measure of tumour response. Broadly, pooling experience, it would appear that changes in [F-18]FDG tumour uptake following one or two cycles of chemotherapy treatment was related to ultimate clinical responses. Patients showing most reduction in [F-18]FDG uptake achieved the best clinical responses. Data were also available on the effect of chemotherapy on normal tissues and some data on the effect of radiotherapy and tumour response. It was concluded that changes in [F-18]FDG uptake as measured with PET may provide useful information on clinical as well as subclinical response of tumours to anticancer therapy. This could be useful as a guide to early response to therapy as well as providing functional assessment of residual masses of disease. More specific markers of cellular proliferation e.g. [(11)]thymidine, or [C-11]- amino acids may provide even more accurate information. A strategy was outlined whereby PET scanning protocols could parallel EORTC early clinical trials so that [F-18]FDG response information could supplement phase I and II clinical studies. Following these developments, an EORTC study group was formed under the auspices of the EORTC research branch, and the strategy for future development in Europe outlined..